Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma

By /

Takeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.

Scroll to Top